Longeveron Inc. (LGVN) News
Filter LGVN News Items
LGVN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LGVN News Highlights
- For LGVN, its 30 day story count is now at 4.
- Over the past 2 days, the trend for LGVN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- DEC and DRUG are the most mentioned tickers in articles about LGVN.
Latest LGVN News From Around the Web
Below are the latest news stories about LONGEVERON INC that investors may wish to consider to help them evaluate LGVN as an investment opportunity.
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMIAMI, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 1,355,301 shares of its |
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.74 |
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMIAMI, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,355,301 of its shares of common stock at a purchase price of $1.62 |
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s DiseaseNew clinical data showed that Lomecel-B™ improved cognitive function in multiple measures in a dose-response fashion Caregiver ratings documented improved quality of life in Lomecel-B™ treated patientsMRI Biomarker study data showed that Lomecel-B™ countered loss of brain volume in multiple areas associated with Alzheimer’s disease, reduced brain neuroinflammation and improved cerebral blood flow Overall results confirmed the drug product’s therapeutic potential in the treatment of mild Alzheime |
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel |
Long-term Survival Data from Longeveron’s ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart AssociationExtended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing in Phase 2 ELPIS II trial - MIAMI, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syn |
Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call TranscriptLongeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript November 10, 2023 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. Operator: Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal […] |
Longeveron Reports Third Quarter 2023 Results and Provides Corporate UpdateTop Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association $4 Million in Equity Financing Secured in Registered Direct Offering ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Compan |
LGVN Continues to Show ProgressBy Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of 2,424,243 shares and |
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial results prior to the market open on Friday November 10, 2023. The Company will host a conference call and webcast that day to discuss the results, and provide an update on its clinical programs and corp |